ClinConnect ClinConnect Logo
Search / Trial NCT02167243

A Reinforcement Approach to Improve Diabetes Management

Launched by YALE UNIVERSITY · Jun 16, 2014

Trial Information

Current as of May 18, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. age 12-21 years old;
  • 2. diagnosis of type 1 diabetes (T1D) \>12 months via ADA guidelines
  • 3. receiving diabetes treatment at Yale Pediatric Diabetes Clinic and not meeting clinical care guidelines
  • 4. SMBG user with clinical recommendations to test \>4 times/day and using a device that allows for remote uploading (e.g., Aviva, Contour, Freestyle, Lifescan, etc.; equipment for uploading will be provided);
  • 5. access to a computer with internet for uploading and sending SMBG data;
  • 6. access to a cell phone with text messaging capabilities and willing to text after SMBG testing and receive messages about reinforcement;
  • 7. English speaking, able to read at \>5th grade level, and pass an informed consent quiz; and adequate knowledge of insulin dosing and dietary recommendations for managing T1D.
  • Exclusion Criteria:
  • 1. have a major psychiatric or neurocognitive disorder (e.g., severe learning impairment) that would inhibit participation;
  • 2. have a major visual impairment;
  • 3. have a significant other medical condition that impacts diabetes management (e.g., asthma, rheumatoid arthritis, or other condition that requires steroid treatment);
  • 4. plan to switch insulin delivery mode (injection to pump or vice versa) in the next 12 months, or have recently switched;
  • 5. are participating in another clinical trial.

About Yale University

Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.

Locations

New Haven, Connecticut, United States

Patients applied

0 patients applied

Trial Officials

William Tamborlane, MD

Principal Investigator

Yale University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials